TRODELVY is a type of treatment called an antibody-drug conjugate (ADC) that is designed to work differently than traditional chemotherapy. It is designed to deliver powerful anticancer medicine directly into cells with Trop-2 proteins.
Information from laboratory studies suggest that this is how TRODELVY works. The clinical benefit of these observations is unknown.
Understanding what makes each treatment different can be confusing. This video will help break down the science to show you how TRODELVY is designed to work. Think of TRODELVY like a cargo ship designed to deliver anticancer medicine directly to cells with Trop-2 proteins. Watch to learn about TRODELVY from an oncologist and some unexpected guests.
Scientists discovered that patients with certain types of cancer have tumor cells that often contain more Trop-2 protein than normal cells (or noncancer cells). TRODELVY binds to cells with Trop-2.
TRODELVY attaches to Trop-2
Once attached, TRODELVY enters the cancer cell
Once TRODELVY enters, the anticancer medicine is released, killing the cell
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract that have spread (metastatic) or cannot be removed by surgery, and who have received a platinum-containing chemotherapy medicine and also received an immunotherapy medicine.
TRODELVY is approved based on medical studies that measured how many patients responded and how long they responded. Continued approval may depend on benefit demonstrated in additional medical studies.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.
Allergic and infusion-related reactions which can be serious and life-threatening. Tell your healthcare provider or nurse right away if you get any of the following symptoms during your infusion of TRODELVY or within 24 hours after: swelling of your face, lips, tongue, or throat; hives; skin rash, itching, or flushing of your skin; fever; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; or chills or shaking chills (rigors).
Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting along with medicines to take home with instructions about how to take them. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose or stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.
Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.
The most common side effects of TRODELVY include feeling tired or weak, hair loss, decreased red blood cell count, constipation, decreased appetite, rash, and stomach-area (abdominal) pain or discomfort.
These are not all of the possible side effects of TRODELVY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please click to see Important Facts about TRODELVY, including Important Warning.